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Large granular lymphocyte and prolymphocytic leukaemias are rare chronic lymphoproliferative disorders. 
Large granular lymphocyte leukaemias consist of indolent disorders such as T-cell large granular lymphocyte 
and chronic lymphoproliferative disorder of natural killer cells and the very rare but aggressive natural killer 
cell leukaemia. Treatment of the indolent large granular lymphocyte leukaemias is necessary in case of symp-
tomatic cytopaenias or non-haematological autoimmune disorders. First line therapy of these two disorders 
is based on three immunosuppressive drugs: methotrexate, cyclophosphamide and cyclosporine A. Aggres-
sive natural killer cell leukaemia needs an L-asparaginase containing regimen as induction followed by 
allogeneic stem cell transplantation to prolong remission. T-cell prolymphocytic leukaemia always follows 
an aggressive course even after an indolent onset. The optimal treatment strategy should exist of remission 
induction with alemtuzumab intravenously followed by autologous or allogeneic stem cell transplantation. 
Treatment indications for B-cell prolymphocytic leukaemia follow the criteria described by the chronic 
lymphocytic leukaemia guidelines. After induction with fludarabine, cyclophosphamide, rituximab or benda-
mustine in patients without a p53 mutation and/or a 17p deletion and alemtuzumab in case of a p53 mutation 
and/or a 17p deletion, stem cell transplantation must be considered.  
(Belg J Hematol 2016;7(3):103-11)
Part I: Large Granular Lymphocyte 
Leukaemias
Large granular lymphocytes (LGLs) represent 10-15% 
of normal peripheral blood mononuclear cells. LGLs 
are large lymphocytes showing an eccentric nucleus 
and abundant cytoplasm with typical azurophilic 
granules. They are derived from two different lineages: 
85% are CD3+ CD56- CD57+ T cells and represent 
antigen activated cytotoxic T lymphocytes, whereas 
the remaining 15% are CD3- CD56+ CD57- Natural 
Killer (NK) cells.1 Dysregulation of cell signalling path-
ways, particularly the JAK/STAT3 axis, leads to loss of 
apoptosis and to proliferative disorders of these LGL 
 
cells.2 Following the 2008 WHO classification of tumours 
of hematopoietic and lymphoid tissues, LGL leukae-
mias encompass three distinct entities (Table 1):
-  T cell LGL leukaemia, consisting of a clonal prolifera-
tion of CD3+ LGLs.
-  Aggressive NK-cell leukaemia, corresponding to an 
accumulation of NK CD3- LGL cells with an aggressive 
behaviour.
-  Chronic lymphoproliferative disorder of NK cells, 
a chronic and indolent CD3- LGL lymphocytosis. It 
is not clear whether this entity represents a benign 
disorder or a chronic phase of NK cell LGL leukaemia.
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LGL leukaemia represents 2-5% of the chronic lym-
phoproliferative diseases in western countries and up 
to 6% in Asia. Indolent T-LGL represents the more 
frequent disorder of the group occurring in 85% of 
cases.3 The disease affects men and women in the same 
proportion at a median age of 60 years (y) with only 
10% being younger than 40 y.4
T-LGL leukaemias have an indolent course with a 
median overall survival (OS) of more than ten years. 
Rare aggressive forms have been described and generally 
affects younger people.5 Cytopaenias, recurrent bacte-
rial infections, autoimmune disorders and splenomegaly 
are the main clinical manifestations of the disease. Up 
 
to 80% of the patients with T-LGL leukaemia present 
with neutropenia, which can be either asymptomatic or 
associated with recurrent bacterial infections.4,6 Anaemia 
is observed in 50% of T-LGL patients and may be secon-
dary to pure red cell aplasia (PRCA) or autoimmune 
haemolytic anaemia. Thrombocytopenia is moderate 
and less frequent (20%), including cases of immune 
thrombocytopenic purpura.4,6 Rheumatoid arthritis is 
the most commonly associated non-hematologic auto-
immune disorder, occurring in around 30% of cases.4,6 
Other autoimmune diseases are described as case 
reports.7 Finally, association with B cell lymphoid neo-
plasms and myelodysplasia is also observed.7 B symp-
toms are mentioned in 20-40% of patients.
Table 1. Characteristics of T-LGL, aggressive NK leukaemia and T-PLL.
T-LGL Aggressive NK-L T-PLL
Median age 60 y 39 y 65 y
Clinical course Indolent Very aggressive Aggressive 
Clinical features Splenomegaly, cytopaenia, 
auto-immune manifestations




nopathies, skin manifestations, 
pleuro-peritoneal effusions
Peripheral lymphocytosis > 2000/mm3 >10000/mm3 >100000/mm3
EBV infection association
Morphology Large lymphocytes Large lymphocytes Medium sized lymphocytes
Abundant cytoplasm with
azurophilic granules
Abundant cytoplasm, azurophilic 
granules
Basophilic cytoplasm with blebs
Eccentric nucleus Eccentric nucleus Round nucleus with nucleolus
Small cell and cerebriform variants
Immunophenotype CD3+ CD8+ CD16+ CD57+ CD3−, CD8+, CD4− CD2+, CD3+, CD5+
CD56− CD28− CD56+, CD16+ CD7++; CD52++
TCR αβ+; 10% TCR γδ+ TCR αβ−; TCR γδ− CD4/CD8 variable
CD1a−; TdT−
Cytogenetics t(14;14); inv 14; t(X;14); iso8q
Molecular biology Clonality of TCR γ chain 
rearrangement
−
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Sustained (> 6 months) expansion of clonal T-LGLs in 
peripheral blood with a characteristic immunopheno-
type and typical symptoms or associated immune dis-
eases, establishes the diagnosis of T LGL leukaemia. 
Most patients have T-LGLs above 2000/mm3 but a lower 
count does not exclude the diagnosis, especially in 
symptomatic patients. The demonstration of bone 
marrow infiltration with monoclonal LGLs can be 
helpful in the diagnosis of these patients.8 The typical 
immunophenotype corresponds to activated cytotoxic 
T cells expressing CD3, CD8, CD16, CD57, TCR αβ 
and no expression of CD56, CD28 and CD4. Some 
cases, however, express CD4 with or without CD8, and 
around 10% are TCR γδ. Clonality is usually demon-
strated using polymerase chain reaction analysis of the 
TCR -γ-chain rearrangement but studies of the TCR β 
chain variable domain repertoire with flow cytometry 
is another possibility in assessing monoclonality.7
Aggressive NK cell leukaemia
Aggressive NK cell leukaemia is a rare disease making 
up about 10% of the LGL proliferations with a signifi-
cantly greater incidence in Asia. The patients are younger 
than in T LGL leukaemia (median age 39 y) and EBV 
infection is commonly associated with the disease.3,9 
Aggressive NK cell leukaemia presents as an acute 
illness with B symptoms, significant lymphocytosis, 
hepatosplenomegaly, lymphadenopathy and severe cyto-
paenia. Liver dysfunction, multi-organ failure and he-
mophagocytosis may occur. The median OS is only 
two months.9 These LGLs show the following immuno-
phenotype: CD3-, CD4-, CD8+, TCRαβ -, TCR γδ-, 
CD16+, CD56+. Clonality is more difficult to demon-
strate except in the case of cytogenetic abnormalities.
Chronic lymphoproliferative disorder of NK cells
Chronic lymphoproliferative disorder of NK cells is also 
an indolent disease with good prognosis that represents 
5% of all LGL expansions. Clinical and haematological 
features are similar to T LGL leukaemia except that 
circulating LGLs present a NK phenotype (CD3-, CD4-
, CD8-, CD16+, and CD56+).10
Treatment (Table 2)
T LGL leukaemia and chronic lymphoproliferative disorder 
of NK cells
As T LGL leukaemia and chronic lymphoproliferative 
disorder of NK cells have a similar indolent evolution, 
indications for treatment and therapeutic options are 
also similar.
Indications for treatment
•  Severe neutropenia (< 500/mm3)
•  Moderate neutropenia (> 500/mm3) with recurrent 
infections
•  Symptomatic or transfusion dependent anaemia
•  Severe thrombocytopenia (< 50,000/mm3)
•  Associated non-hematologic autoimmune disorder 
requiring therapy
Frontline treatment 
There is no well-defined standard of care for LGL leukae-
mias and recommendations are essentially established 
on the basis of small retrospective case-series. However, 
a recent phase II prospective multicentre trial of the 
Eastern Cooperative Oncology Group (ECOG) brings 
some new information about how to treat these patients.11
First line therapy is based on three immunosuppressive 
drugs: methotrexate (MTX), cyclophosphamide (C) and 
cyclosporine (CyA). Clinician’s choice is guided by co-
morbidities and associated autoimmune manifestations:
Methotrexate
In the above mentioned ECOG study, oral MTX ad-
ministered at a dose of 10 mg/m2 once a week induced 
an overall response rate (ORR) of 38% (95% confi-
dence interval (CI) 26-53%). These results are in line 
with the retrospective analysis of the French cohort of 
LGL leukaemia.4
In practice, MTX is given at a dose of 10 mg/m2, once 
weekly until progression or intolerance. As the re-
sponse is slow to develop, the treatment must be con-
tinued for at least four months before stopping due to 
inefficiency. MTX is the recommended drug in case of 
associated autoimmune disease (RA). Prednisone can 
be associated during the first month to accelerate the 
response.
Cyclophosphamide
In a recent retrospective series of 45 previously untreated 
LGL patients, an ORR of 71% was observed with C. 
Relapse occurred in only 13% of the patients during 
the median follow up of 35 months (mo) (range 3,8-
277 mo).12 As second line treatment, in case of no 
response to methotrexate, the ORR to C still reached 
65%.4,11 Altogether, these results compare favourably 
with the ORR obtained in first line with MTX but to 
date, results of a randomised prospective trial assessing 
MTX versus C in first line therapy are not available.
In practice, C is given orally at a dose of 100 mg each 
day with the possibility to decrease to 50 mg in respond-
3Belgian Journal of Hematology   Volume 7, Issue 3, June 2016
106
Table 2. Treatment of LGL leukaemias.
T-LGL and chronic lymphoproliferative disorder of natural killer (NK) cells
Drug Schedule Indications
Cyclophosphamide (C) • 100mg/day orally
• Max 12 months
• First choice 
• Pure red cell aplasia
Methotrexate (MTX) • 10mg/m2 once a week
• Until progression or toxicity
• Preferential drug in rheumatoid arthritis
Cyclosporine (CyA) • 5 -10 mg/kg in 2 divided doses
•  Therapeutic level: 200 to 400 ng/ml until response 
then tapering to the lowest effective dose
• Pure red cell aplasia
• HLA DR4 phenotype
Purine analogues • Refractory disease
Alemtuzumab • Refractory disease
Splenectomy •  Refractory disease with splenomegaly  
and /or immune cytopaenia
Aggressive NK leukaemia 
L-Asparaginase • SMILE protocol
• L-Asparaginase monotherapy
• Consolidation with allogeneic SCT
Table 3. Treatment of PLL.
T-PLL 
Drug Schedule Indications
Alemtuzumab •  First week dose escalation 3-10-30mg,  
afterwards 30mg, 3x/week
• IV route of administration
• Premedication required
• Pneumocystis and Herpes prophylaxis
• CMV monitoring
• First line therapy
• Consolidation with auto/allogeneic SCT
Pentostatin + Alemtuzumab • Suboptimal response to single agent Alemtuzumab
• Effusions / Liver infiltration
Bendamustine • Refractory disease
Purine analogues • Refractory disease
B-PLL 
FCR / BR • Absence of TP53 mutation
• Consider consolidation with auto/allogeneic SCT
Alemtuzumab • Presence of TP53 mutation
• Consider consolidation with auto/allogeneic SCT
BCR inhibitors / 
New anti-CD20mAb
• To be evaluated
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ing patients. The duration of treatment is minimum 
four months and maximum nine to twelve months to 
avoid secondary toxicity. Of note, C has shown particu-
lar efficacy in cases of PRCA.13,14
Cyclosporin
CyA is a therapeutic alternative in cases of MTX/C 
failure. Doses up to 5-10 mg/kg a day in two divided 
doses are progressively introduced and adapted to 
maintain a therapeutic level between 200-400 ng/ml. 
ORR is variable according to the reported case series 
with a medium ORR of 56% (range 21-100%). At 
response, CyA is slowly tapered to the lowest effective 
dose.14-16 However, it is advised to maintain CyA unless 
emergence of side effects. The drug seems of particular 
interest in patients suffering from PRCA or having a 
HLA DR4 phenotype.15
Treatment of relapsed or refractory 
disease
Relapsed disease can be either retreated with the same 
drug or with one of the two other major immuno- 
suppressive drugs, depending on the time of relapse. 
A patient resistant to one of these drugs may respond 
to one of the others. In refractory disease with no 
response to MTX, C and CyA, several alternative solu-
tions may be considered. 
Purine analogues (fludarabine, pentostatin, or 2-CDA) 
showed ORR up to 80% in a retrospective series of 
LGL patients but the results have to be considered 
with caution because of the very small number of 
reported case series.7 Alemtuzumab (A) can be consi-
dered in case of failure to purine analogues if leukemic 
cells express CD-52, bearing in mind the high risk of 
opportunistic infections. Splenectomy may be helpful 
in refractory patients with symptomatic splenomegaly 
or autoimmune cytopaenia. Myeloid growth factors 
can be used in case of febrile neutropenia. CHOP or 
CHOP-like regimens seem ineffective. Finally, inhibi-
tors of JAK/STAT pathway are new emerging drugs 
with promising activity to induce apoptosis in LGL 
leukemia.17,18
Treatment of NK cell aggressive leukaemia
NK cell aggressive leukaemia has a very poor prognosis 
characterised by chemo-resistance. Prompt diagnosis 
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Figure 1. Morphology of T-PLL. Male, 62 y, night sweats, diffuse lymphadenopathies and splenomegaly; white blood cell count 
213,000/mm3 with 90% atypical lymphoid cells (medium-sized cells with abundant basophilic cytoplasm, round to oval nuclei 
with fine chromatin and clear nucleoli and a regular nuclear and cytoplasmic outline); immunophenotype: CD2, CD4, CD5, 
CD7, cyCD3 positive, TdT, Cd1a, CD8, TCR αβ and TCR γδ negative; conventional karyotype showed typical T-PLL aberrations: 
46,XY,t(4;15)(q13;p13),+i(8)(q10),del(11)(q13),inv(14)(q11q32),-22[2]46,XY[8]. 
Courtesy of Dr C. Brusselmans, UZ Leuven.
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and treatment are of primordial importance in this rare 
but rapidly fatal disease. L-asparaginase monotherapy 
or L-asparaginase containing regimens (SMILE proto-
col) followed by allogeneic stem cell transplantation 
(SCT) have been shown to induce prolonged remis-
sions.19-22 
Part II: Chronic Prolymphocytic 
Leukaemia
T cell prolymphocytic leukaemia
Presentation and diagnosis
T cell prolymphocytic leukaemia (T-PLL) is a rare post-
thymic T cell neoplasm. This haematological malignancy 
represents around 2% of mature lymphocytic leukaemia 
in adults and up to 30% of mature T-cell neoplasms 
with leukemic presentation.23,24 T-PLL has  a median 
age of 65 y at diagnosis with a male to female ratio of 
2:1.25 A higher incidence is seen in patients suffering 
from the genetic disorder ataxia telangiectasia; the me-
dian age at onset in this condition is much younger.26 
Clinical course is mostly aggressive, although some 
patients may have an initial indolent phase. Major lym-
phocytosis (> 100,000/mm3 with 90% prolymphocytes), 
hepatosplenomegaly, and lymphadenopathies are typi-
cal signs at presentation.27 Skin manifestations such 
as nodular lesions, maculopapular rash or, more rarely, 
erythroderma are described. Pleuro-peritoneal effusions, 
peri-orbital or conjunctival oedema and central nervous 
system infiltration may occur.24,27
T-PLL identification should be based on the integration 
of clinical manifestations, morphological description 
of the peripheral blood film, flow cytometry and genetic 
analysis. Typical T prolymphocytes (T-PL) are medium-
sized cells with round to oval nuclei and visible nucleoli 
(Figure 1). Cytoplasm is moderately abundant, baso-
philic without granules and may present protrusions 
(blebs). Less frequently, cells are small with invisible 
nucleoli (small cell variant; 20%) or have an irregular 
nuclear outline resembling the cerebriform nucleus of 
Sézary cells (cerebriform variant).27 T-PL have a mature 
post-thymic phenotype (TdT-, CD1a-, CD5+, CD2+, or 
CD7+). Of note, CD7 expression seems more intense 
in T-PLL compared to other mature T cell leukaemias. 
Sixty percent of cases are CD4+/CD8-; 25% CD4+/
CD8+ and 15% CD4-/CD8+. All cases express CD3 
and TCRβ as surface or intracytoplasmic T cell markers. 
T-PL express intensively the CD52 membrane protein.25,27 
T cell receptor genes are clonally rearranged. Abnor-
malities of chromosome 14 are seen in 90% of T-PLL 
and lead to the expression and activation of the proto-
oncogene TLC1 (inv(14), t(14;14)(q11;q32)) or its homo-
log MTCP1 (t(X;14)(q28;q11)).28,29 Abnormalities of chro-
mosome 8 (t(8;8), trisomy 8q, idic(8p11)) are seen in 
approximately 66% of patients and may lead to c-myc 
overexpression.30 Other recurrent cytogenetic defects 
described involve several chromosomes (6, 9, 12, 17, 
22, etc.).24 Molecular investigations may identify ATM 
gene deletions or missense mutations as well as acti-
vating mutations of JAK1 and JAK3 tyrosine kinase. 
Moreover, a recent T-PLL genomic sequencing study 
identified recurrent mutations in the IL-2 Rγ-JAK1-
JAK3-STAT5 signalling pathway offering hope for new 
therapeutic strategies.31
Treatment
With conventional alkylating-based chemotherapy prog-
nosis of T-PLL is poor with OS of less than one year.27 
Today, the optimal treatment strategy should exist of 
remission induction with intravenous (IV) alemtuzumab 
followed by autologous or allogeneic SCT as consoli-
dation whenever possible.23 Alemtuzumab IV has demon-
strated a high ORR and CR in pre-treated (ORR 51-76%, 
CR 40-60%) and in untreated patients (ORR 91%, CR 
81%). Of note, the subcutaneous route of alemtuzumab 
administration is less effective and is not recommen- 
ded.32,33 After dose escalation with appropriate pre-
medication (first week 3-10-30 mg), 30 mg three times 
a week is maintained until maximal response (maximum 
of sixteen weeks) or intolerable toxicity. Prophylaxis for 
Pneumocystis jiroveci and Herpes viruses as well as 
CMV infection monitoring have to be performed. Purine 
analogues, and particularly pentostatin, have been stud-
ied in the treatment of T-PLL. A retrospective analysis 
of pentostatin administered in 55 patients showed an 
ORR of 45% with 9% CR.34 The association of pento-
statin and alemtuzumab was studied in a prospective 
phase II study in thirteen T-PLL patients. An ORR of 69% 
and 62% CR with a lot of infectious complications.35 
Therefore, the combination of pentostatin-alemtuzumab 
should be reserved to obtain a CR in patients with sub-
optimal response to single agent alemtuzumab or in 
patients with pleuro-peritoneal effusions or liver infil-
tration known to be more resistant to the antibody 
alone.
The best OS and progression free survival (PFS) are 
observed in patients treated with first line alemtuzumab 
who achieved a CR. However, the majority will relapse 
within one year. Therefore, intensification therapy is 
required whenever it’s possible. Allogeneic SCT achieves 
an OS and PFS of only 0-30% due to a treatment related 
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toxicity (TRM) up to 40%.36,37 Autologous SCT led to 
greater relapse rates than allogeneic SCT but induced 
less TRM reaching approximately the same OS.38 Age, 
donor availability and co-morbidities will guide the 
physician in the choice of transplantation type and 
conditioning regimen. 
Rechallenge with alemtuzumab may be considered if 
relapse occurs six months after the first administration 
and if tumour cells still express CD52. In alemtuzumab 
refractory patients, purine analogue or bendamustine 
based regimens are good options.39,40 
B-cell prolymphocytic leukaemia
Presentation and diagnosis
B cell prolymphocytic leukaemia (B-PLL) is an even more 
rare neoplasm characterised by mature B cell prolifera-
tion in blood, bone marrow and spleen. The definition 
based on the WHO haematological malignancies clas-
sification, includes blood and bone marrow infiltration 
by more than 55% B prolymphocytes (B-PL). Atypical 
chronic lymphocytic leukaemia (CLL), CLL with pro-
lymphocytic transformation (less than 55% B-PL mixed 
with typical CLL lymphocytes), and mantle cell lym-
phoma with t(11;14) (q13;q32) and cyclin D1 rearrange-
ment are excluded from this entity. However, a recent 
gene expression profiling and immunophenotyping 
study suggests that B-PLL could be a heterogenic group 
of pathologies ranging from a subgroup close to CLL to 
a subgroup with full overlap with MCL.41 The disease 
represents 1% of chronic B cell leukaemias and is pre-
dominant in elderly patients (65-70 y) with an equal sex 
distribution. Rapidly progressive lymphocytosis (with 
typically more than 90% B-PL in peripheral blood) and 
massive splenomegaly are the most common features 
of the disease. Anaemia and thrombocytopenia are 
present in 65% and 35% of cases, respectively. Lym-
phadenopathies are not prominent and B symptoms 
are frequent. 
As in T-PLL, diagnosis is based upon clinical presenta-
tion, morphology, flow cytometry and genetic assessment. 
Correct identification of B-PLL may be difficult because 
of similarities with other B cell malignancies (CLL, MCL, 
SMZL, and HCL). In B-PLL, peripheral blood shows 
more than 55% monomorphic B-PLs. These cells have 
twice the size of a CLL cell, have a nucleus with mode-
rately condensed chromatin and a prominent nucleolus, 
have more abundant cytoplasm than a normal lym-
phocyte and show a regular outline. The bone marrow 
biopsy reveals a nodular or interstitial infiltration without 
proliferation centres as observed in CLL.24 Pan B cell 
markers (CD20, CD22, CD24, FMC7, and CD79b) and 
surface immunoglobulin (IgM or IgM/IgD) are strongly 
expressed. Most cases are CD5- and CD23-, although 
a few cases can express these antigens. CD10, CD11c, 
CD103, CD25, cyclinD1, and SOX-11 are not expressed. 
This means that the Catovsky score (CD5+, CD23+, 
surface immunoglobulin weak, FMC7-, CD79b weak) 
does not reach more than one, rarely two, and excludes 
the diagnosis of CLL.42 Complex karyotypes are com-
mon. Deletions of 17p and p53 mutations are present in 
more than 50% of cases.43 Del 13q24 is also frequently 
described.44 At the molecular level, c-MYC and AKT 
genes over-expression and p53 downregulation have 
been identified in gene expression profiling studies.45
Treatment 
Because of the rarity of the disease, there are few studies 
on B-PLL treatment. Treatment indications follow the 
criteria described by the CLL guidelines meaning that 
only symptomatic patients have to be treated. In patients 
without p53 mutations/17p deletions, fludarabine, cyclo-
phosphamide and rituximab (FCR) or bendamustine 
(B)R are recommended whereas in the presence of p53 
mutations/17p deletions, alemtuzumab is indicated. 
Chlorambucil is rarely useful but splenectomy or splenic 
irradiation may be performed as palliative support. In 
young and fit patients who achieve CR, SCT has to be 
considered. New monoclonal anti-CD20 antibodies and 
inhibitors of BCR signalling may be therapeutic tools 
but have to be evaluated in this disease.
References
1. Sokol L, Loughran TP. Large granular lymphocyte leukaemia. The Oncologist. 
2006;11(3):263-73. 
2. Schade AE, Wlodarski MW, Maciejewski JP. Pathophysiology defined by 
altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in 
leukemic large granular lymphocytes. Cell Cycle Georget Tex. 2006;5(22):2571-4. 
3. Steinway SN, LeBlanc F, Loughran TP. The pathogenesis and treatment of 
large granular lymphocyte leukaemia. Blood Rev. 2014;28(3):87-94. 
4. Bareau B, Rey J, Hamidou M, et al. Analysis of  a French cohort of patients 
with large granular lymphocyte leukaemia: a report on 229 cases. Haematologica. 
2010;95(9):1534-41. 
5. Tordjman R, Macintyre E, Emile JF, et al. Aggressive acute CD3+, CD56- 
T cell large granular lymphocyte leukaemia with two stages of maturation arrest. 
Leukemia. 1996;10(9):1514-9. 
6. Loughran TP. Clonal diseases of large granular lymphocytes. Blood. 1993; 
82(1):1-14. 
7. Lamy T, Loughran TP. How I treat LGL leukaemia. Blood. 2011;117(10):2764-74. 
8. Semenzato G, Zambello R, Starkebaum G, et al. The lymphoproliferative disease 
of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256-60. 
109
Practice Guidelines
3Belgian Journal of Hematology   Volume 7, Issue 3, June 2016
110
9. Song S-Y, Kim WS, Ko Y-H, et al. Aggressive natural killer cell leukaemia: 
clinical features and treatment outcome. Haematologica. 2002;87(12):1343-5. 
10. Poullot E, Zambello R, Leblanc F, et al. Chronic natural killer lymphoproliferative 
disorders: characteristics of an international cohort of 70 patients. Ann Oncol. 
2014;25(10):2030-5. 
11. Loughran TP, Zickl L, Olson TL, et al. Immunosuppressive therapy of LGL 
leukaemia: prospective multicentre phase II study by the Eastern Cooperative 
Oncology Group (E5998). Leukemia. 2015;29(4):886-94. 
12. Moignet A, Hasanali Z, Zambello R, et al. Cyclophosphamide as a first-line 
therapy in LGL leukaemia. Leukemia. 2014;28(5):1134-6. 
13. Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and out-
comes following immunosuppressive therapy in large granular lymphocyte 
leukaemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan 
for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555-9. 
14. Go RS, Li CY, Tefferi A, et al. Acquired pure red cell aplasia associated with 
lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98(2):483-5. 
15. Battiwalla M, Melenhorst J, Saunthararajah Y, et al. HLA-DR4 predicts 
haematological response to cyclosporine in T-large granular lymphocyte lym-
phoproliferative disorders. Br J Haematol. 2003;123(3):449-53. 
16. Sood R, Stewart CC, Aplan PD, et al. Neutropenia associated with T-cell 
large granular lymphocyte leukaemia: long-term response to cyclosporine therapy 
despite persistence of abnormal cells. Blood. 1998;91(9):3372-8. 
17. Bilori B, Thota S, Afable MG, et al. Inhibition Of The JAK/STAT Signaling 
Pathway As a Novel Therapy In CD8+ T-Large Granular Lymphocyte Leukemia. 
Blood. 2013;122(21):3902.
18. Bilori B, Thota S, Clemente MJ, et al. Tofacitinib as a novel salvage therapy 
for refractory T-cell large granular lymphocytic leukaemia. Leukemia. 2015; 
29(12):2427-9.
19. Yamaguchi M, Suzuki R, Kwong Y-L, et al. Phase I study of dexamethasone, 
methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy 
for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell 
lymphoma and leukaemia. Cancer Sci. 2008;99(5):1016-20. 
20. Ichikawa S, Fukuhara N, Yamamoto J, et al. Successful Allogeneic Hemato-
poietic Stem Cell Transplantation for Aggressive NK Cell Leukemia. Intern Med. 
2010;49(17):1907-10. 
21. Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 
western patients with extranodal NK/T-cell lymphoma and leukaemia and a 
review of the literature. Ann Oncol. 2009;20(1):110-6. 
22. Takahashi H, Sakai R, Hattori Y, et al. Successful disease control with 
L-asparaginase monotherapy for aggressive natural killer cell leukaemia with 
severe hepatic failure. Leuk Lymphoma. 2013;54(3):662-4. 
23. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management 
of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). 
Br J Haematol. 2011;153(4):451-85. 
24. Dearden C. How I treat prolymphocytic leukaemia. Blood. 2012;120(3):538-51. 
25. Krishnan B, Matutes E, Dearden C. Prolymphocytic leukaemias. Semin 
Oncol. 2006;33(2):257-63. 
26. Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prog-
nosis of malignancies in ataxia-telangiectasia: a report from the French national 
registry of primary immune deficiencies. J Clin Oncol Off J Am Soc Clin Oncol. 
2015;33(2):202-8. 
27. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory 
features of 78 cases of T-prolymphocytic leukaemia. Blood. 1991;78(12):3269-74. 
28. Narducci MG, Stoppacciaro A, Imada K, et al. TCL1 is overexpressed in 
Key messages for clinical practice
1. T-LGL and chronic lymphoproliferative disorder of NK cells are mostly indolent disorders. Treatment 
is necessary in case of symptomatic cytopaenias or non-haematological autoimmune disorders.
2. First line therapy of T-LGL and chronic lymphoproliferative disorder of NK cells is based on three 
immunosuppressive drugs: MTX, C and CyA. Clinician’s choice is guided by co-morbidities and 
associated autoimmune manifestations.
3. Aggressive NK cell leukaemia is a rare LGL proliferation in western countries. Induction treatment 
with a L-asparaginase containing regimen followed by allogeneic SCT has the highest chance to 
obtain prolonged remissions.
4. T-PLL always follows an aggressive course. The optimal treatment strategy should consist of remission 
induction with alemtuzumab IV followed by autologous or allogeneic SCT whenever possible.
5. Treatment indications for B-PLL follow the criteria described by the CLL guidelines. After induction 
with FCR, BR in patients lacking a p53 mutation or deletion or alemtuzumab in case of a p53 mutation 
or deletion, SCT must be considered. 
Belgian Journal of Hematology   Volume 7, Issue 3, June 2016
111
patients affected by adult T-cell leukaemias. Cancer Res. 1997;57(24):5452-6. 
29. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the 
human chromosome Xq28 translocated to the T cell receptor alpha/delta locus 
in mature T cell proliferations. Oncogene. 1993;8(9):2475-83. 
30. Maljaei SH, Brito-Babapulle V, Hiorns LR, et al. Abnormalities of chromo-
somes 8, 11, 14, and X in T-prolymphocytic leukaemia studied by fluorescence 
in situ hybridization. Cancer Genet Cytogenet. 1998;103(2):110-6. 
31. Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing 
reveals mutational landscape of T-cell prolymphocytic leukaemia. Blood. 
2014;124(9):1460-72. 
32. Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolym-
phocytic leukaemia: comparing efficacy in a series treated intravenously and a 
study piloting the subcutaneous route. Blood. 2011;118(22):5799-802. 
33. Damlaj M, Sulai NH, Oliveira JL, et al. Impact of Alemtuzumab Therapy 
and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center 
Experience. Clin Lymphoma Myeloma Leuk. 2015;15(11):699-704.
34. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treat-
ment of T-cell malignancies: analysis of response rate in 145 patients according 
to disease subtype. J Clin Oncol. 1994;12(12):2588-93
35. Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of 
fludarabine, mitoxantrone, and cyclophosphamide induction followed by alem-
tuzumab consolidation is effective in T-cell prolymphocytic leukaemia. Cancer. 
2013;119(12):2258-67. 
36. Guillaume T, Beguin Y, Tabrizi R, et al. Allogeneic hematopoietic stem cell 
transplantation for T-prolymphocytic leukaemia: a report from the French society 
for stem cell transplantation (SFGM-TC). Eur J Haematol. 2015;94(3):265-9. 
37. Wiktor-Jedrzejczak W, Dearden C, de Wreede L, et al. Hematopoietic stem 
cell transplantation in T-prolymphocytic leukaemia: a retrospective study from 
the European Group for Blood and Marrow Transplantation and the Royal 
Marsden Consortium. Leukemia. 2012;26(5):972-6. 
38. Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alem-
tuzumab in T-cell prolymphocytic leukaemia results in longer survival than after 
alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 
2010;149(6):907-10. 
39. Herbaux C, Genet P, Bouabdallah K, et al. Bendamustine is effective in T-cell 
prolymphocytic leukaemia. Br J Haematol. 2015;168(6):916-9. 
40. Gandhi V, Tam C, O’Brien S, et al. Phase I trial of nelarabine in indolent 
leukaemias. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(7):1098-105. 
41. Van der Velden VHJ, Hoogeveen PG, de Ridder D, et al. B-cell prolymphocytic 
leukaemia: a specific subgroup of mantle cell lymphoma. Blood. 2014;124(3):412-9. 
42. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of 
B-cell disorders and proposal of a scoring system for the diagnosis of CLL. 
Leukemia. 1994;8(10):1640-5.
43. Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell 
prolymphocytic leukaemia. Blood. 1997;89(6):2015-23. 
44. Lens D, Matutes E, Catovsky D, et al. Frequent deletions at 11q23 and 13q14 
in B cell prolymphocytic leukaemia (B-PLL). Leukemia. 2000;14(3):427-30. 
45. Del Giudice I, Osuji N, Dexter T, et al. B-cell prolymphocytic leukaemia and 
chronic lymphocytic leukaemia have distinctive gene expression signatures. 
Leukemia. 2009;23(11):2160-7. 
Practice Guidelines
